Senators seek Ebola priority review 'voucher'
This article was originally published in Scrip
Executive Summary
Two US senators want Ebola added to the list of qualified neglected tropical diseases for which biopharmaceutical makers can gain an FDA priority review voucher if the firms develop drugs or vaccines to treat the deadly virus, which has killed about 5,000 people during the current outbreak.